Bortezomib-containing induction regimens in transplant-eligible myeloma patients: A meta-analysis of phase 3 randomized clinical trials

Cancer

Volumn 119, Issue 23, 2013, Pages 4119-4128

  Nooka, Ajay K ^a   Kaufman, Jonathan L ^a   Behera, Madhusmita ^a   Langston, Amelia ^a   Waller, Edmund K ^a   Flowers, Christopher R ^a   Gleason, Charise ^a   Boise, Lawrence H ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bortezomib containing induction regimen; induction therapy; multiple myeloma; nonbortezomib containing induction regimen; transplant eligible

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; META ANALYSIS; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS REACTIVATION;

BORTEZOMIB-CONTAINING INDUCTION REGIMEN; INDUCTION THERAPY; MULTIPLE MYELOMA; NONBORTEZOMIB-CONTAINING INDUCTION REGIMEN; TRANSPLANT-ELIGIBLE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84888000077     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28325     Document Type: Article

References (23)

1. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
3. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27: 3518-3525.
4. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010; 116: 679-686.
5. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008; 26: 2171-2177.
6. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008; 93: 124-127.
7. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11: 29-37.
8. Jakubowiak AJ, Griffith KA, Reece DE, et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011; 118: 535-543.
9. Kaufman JL, Shah JJ, Laubach JP, et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): initial results of a phase 1 study [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 3034.
10. Moreau P, Attal M, Pegourie B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011; 117: 3041-3044.
11. Harousseau J-L, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28: 4621-4629.
12. Cavo M, Tacchetti P, Patriarca F, et al. GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376: 2075-2085.
13. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012; 120: 1589-1596.
14. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-2955.
15. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62: 1006-1012.
16. Parmar MKB, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815-2834.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis [serial online]. Trials. 2007; 8: 16.
18. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012; 119: 940-948.
19. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120: 9-19.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
21. Egger M, Smith GD, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
22. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005; 106: 3777-3784.
23. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.